The BEACON-LUNG study proposes to collect serum, plasma, tissue, and CT images from patients receiving pembrolizumab or pembrolizumab plus carboplatin-based chemotherapy to help identify patients who may benefit from a more aggressive triplet treatment regimen. As part of the study, patient samples undergo a serum-based pretreatment evaluation of the circulating proteome (hereafter referred to as Primary Immune Response or PIR test). This test utilizes mass spectrometry with machine learning and was developed by Biodesix, Inc. to classify patients as responders or non-responders, which could help identify patients who may benefit from a triplet treatment regimen.
This research study is for treatment naïve advanced stage NSCLC patients with PD-L1 expression ≥50% treated with pembrolizumab monotherapy, or pembrolizumab with chemotherapy.
This trial is sponsored by Biodesix, Inc. (Boulder, CO), a company that specializing in liquid biopsy and lung cancer diagnostics. To learn more about Biodesix, visit their website at https://www.biodesix.com.
Click on topic below for more information.